CN114480167A - Lactococcus lactis MD-622 and application thereof - Google Patents
Lactococcus lactis MD-622 and application thereof Download PDFInfo
- Publication number
- CN114480167A CN114480167A CN202111586675.5A CN202111586675A CN114480167A CN 114480167 A CN114480167 A CN 114480167A CN 202111586675 A CN202111586675 A CN 202111586675A CN 114480167 A CN114480167 A CN 114480167A
- Authority
- CN
- China
- Prior art keywords
- lactococcus lactis
- probiotic
- lactis
- growth
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000194035 Lactococcus lactis Species 0.000 title claims description 46
- 235000014897 Streptococcus lactis Nutrition 0.000 title claims description 45
- 230000012010 growth Effects 0.000 claims abstract description 13
- 239000004382 Amylase Substances 0.000 claims abstract description 11
- 102000013142 Amylases Human genes 0.000 claims abstract description 11
- 108010065511 Amylases Proteins 0.000 claims abstract description 11
- 108010059892 Cellulase Proteins 0.000 claims abstract description 11
- 108091005804 Peptidases Proteins 0.000 claims abstract description 11
- 239000004365 Protease Substances 0.000 claims abstract description 11
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 11
- 235000019418 amylase Nutrition 0.000 claims abstract description 11
- 229940106157 cellulase Drugs 0.000 claims abstract description 11
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 11
- 238000011161 development Methods 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 4
- 239000001963 growth medium Substances 0.000 claims description 14
- 239000006041 probiotic Substances 0.000 claims description 10
- 230000000529 probiotic effect Effects 0.000 claims description 10
- 235000018291 probiotics Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 abstract description 8
- 230000029087 digestion Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 238000012258 culturing Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241001112724 Lactobacillales Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194018 Streptococcaceae Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/231—Lactis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides lactobacillus lactis MD-622 and application thereof. The Lactobacillus lactis MD-622 can promote the production of protease, amylase and cellulase, and has potential capability of promoting the digestion of human intestinal tract. In addition, the lactobacillus lactis MD-622 can promote the growth and development of embryonic stem cells to a certain extent.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to lactococcus lactis MD-622 and application thereof.
Background
Lactococcus lactis (l.lactis) is a prokaryotic microorganism belonging to the phylum firmicutes, class bacilli, order lactobacillales, family streptococcaceae, genus Lactococcus, and is an important model bacterium in the genus Lactococcus.
Lactis are widely present in dairy and plant products, widely used in the food industry, are not pathogenic to humans and animals, and are food grade microorganisms (GRAS) that are generally recognized as safe. However, there are many actual species of lactococcus lactis, and many lactococcus lactis and their effects have not been known and utilized.
Disclosure of Invention
Based on the above, there is a need for lactococcus lactis MD-622 and applications thereof, wherein lactococcus lactis MD-622 can promote in vivo production of protease, amylase and cellulase, improve intestinal discomfort, and promote embryonic stem cell growth and development to a certain extent.
The invention adopts the following technical scheme:
the invention provides lactococcus lactis MD-622 which is preserved in China general microbiological culture Collection center (CGMCC) at 11 months and 15 days 2021, wherein the preservation number is CGMCC No.23902, and the preservation unit address is as follows: beijing in China.
The sequence of the 16S rRNA of the lactococcus lactis is shown in SEQ ID NO. 1.
In some of these embodiments, the culture conditions of lactococcus lactis are: MRS culture medium, pH6.2-6.6.
In some of these embodiments, the lactococcus lactis is capable of producing a protease, an amylase, a cellulase.
The invention also provides a composition containing the lactococcus lactis MD-622 and secretion products or metabolites thereof.
The invention also provides application of the lactococcus lactis MD-622 in preparation of probiotic products. The probiotic product is a medicine, functional food or health-care product for improving intestinal diseases, or the probiotic product is a medicine, functional food or health-care product for promoting the growth and development of embryonic stem cells.
The invention also provides a probiotic preparation which comprises the lactococcus lactis MD-622 and auxiliary materials.
The invention also provides a probiotic preparation which comprises the secretion product of lactococcus lactis MD-622.
The invention has the beneficial effects that:
compared with the prior art, the lactococcus lactis MD-622 is obtained by screening a large number of research tests, and the lactococcus lactis MD-622 can promote in vivo production of protease, amylase and cellulase, improve intestinal health and promote growth and development of embryonic stem cells to a certain extent.
Drawings
FIG. 1 is a photograph of a colony of lactococcus lactis MD-622.
FIG. 2 is an enzyme production test chart of lactococcus lactis MD-622.
Detailed Description
The present invention is further described in detail below with reference to specific examples so that those skilled in the art can more clearly understand the present invention.
The following examples are provided only for illustrating the present invention and are not intended to limit the scope of the present invention. All other embodiments obtained by a person skilled in the art based on the specific embodiments of the present invention without any inventive step are within the scope of the present invention.
In the examples of the present invention, all the raw material components are commercially available products well known to those skilled in the art, unless otherwise specified; in the examples of the present invention, unless otherwise specified, all technical means used are conventional means well known to those skilled in the art.
The key reagent composition is as follows:
MRS culture medium: 10g/L of peptone, 5g/L of beef extract powder, 4g/L of yeast extract powder, 20g/L of glucose, 2g/L of dipotassium phosphate, 2g/L of triammonium citrate, 5g/L of sodium acetate, 0.2g/L of magnesium sulfate, 0.05g/L of manganese sulfate, 15g/L of agar, 801.0 g/L of tween and 6.2 +/-0.2 of pH value.
Example 1 screening of lactic acid bacteria
Taking feces of healthy adults about 25 years old, diluting with distilled water, coating the feces in an MRS (lactic acid bacteria culture medium), carrying out inverted culture at 37 ℃, selecting single colonies with different forms on the culture medium, streaking, continuing to carry out purification culture, and separating strains with the numbers of 5b4M2, cb18M1, PS128, XS10M8, XS14M1 and XS14M 5.
EXAMPLE 2 enzyme production Activity test
The enzyme production activity tests were carried out on strains 5b4M2, cb18M1, PS128, XS10M8, XS14M1 and XS14M5, respectively:
(1) the strains are respectively inoculated into a protease screening culture medium containing 10g/L of skimmed milk powder, 10g/L of peptone and 15g/L of agar powder, and cultured at 37 ℃. Further, the production of protease in the culture broth was examined by the protease hydrolysis loop method.
The statistical results are shown in the following table:
statistics table of protease production of different bacteria (N ═ 3)
(2) Inoculating the above strains with a solution containing 13mM Tris-HCl, 75mM NaCl, and 1.3mM CaCl2(pH8.0), agar 15g/L, 10mg/L rhodamine B, and polyethylene olive oil emulsion 31.25mL, and culturing at 37 deg.C. Further detecting the lipase production condition in the culture solution by using a lipase transparent ring method.
The statistical results are shown in the following table:
statistical table of lipase production of different bacteria (N ═ 3)
Remarking: "-" represents no transparent circles.
(3) Inoculating the above strains into amylase screening culture medium containing 5g/L yeast extract, 15g/L soluble starch, and 15g/L agar powder, respectively, and culturing at 37 deg.C. And further detecting the amylase production condition in the culture solution by adopting an amylase hydrolysis loop method.
The statistical results are shown in the following table:
statistics table for amylase production by different bacteria (N ═ 3)
Remarking: "-" represents none and "+" represents presence.
(4) The strains are respectively inoculated into cellulase screening culture media containing 5g/L of yeast extract, 5g/L of carboxymethyl cellulose and 15g/L of agar powder, and cultured at 37 ℃. And further detecting the cellulase production condition in the culture solution by adopting a cellulase hydrolysis loop method.
The statistical results are shown in the following table:
statistical table of cellulase production of different bacteria (N ═ 3)
Remarking: "-" represents none, and "+" represents presence.
The detection proves that only the cb18m1 strain can simultaneously produce protease, amylase and cellulase. As shown in detail in fig. 2.
The cb18m1 strain is checked and identified, and the 16s sequence of the cb18m1 strain is tested to be 5_ TSS 20211101-027-00230:
ggggcgtgtgctatgatgcagttgagcgctgaaggttggtacttgtaccgactggatgagcagcgaacgggt gagtaacgcgtggggaatctgcctttgagcgggggacaacatttggaaacgaatgctaataccgcataaaaacttta aacacaagttttaagtttgaaagatgcaattgcatcactcaaagatgatcccgcgttgtattagctagttggtgaggtaa aggctcaccaaggcgatgatacatagccgacctgagagggtgatcggccacattgggactgagacacggcccaa actcctacgggaggcagcagtagggaatcttcggcaatggacgaaagtctgaccgagcaacgccgcgtgagtga agaaggttttcggatcgtaaaactctgttggtagagaagaacgttggtgagagtggaaagctcatcaagtgacggta actacccagaaagggacggctaactacgtgccagcagccgcggtaatacgtaggtcccgagcgttgtccggattta ttgggcgtaaagcgagcgcaggtggtttattaagtctggtgtaaaaggcagtggctcaaccattgtatgcattggaaa ctggtagacttgagtgcaggagaggagagtggaattccatgtgtagcggtgaaatgcgtagatatatggaggaaca ccggtggcgaaagcggctctctggcctgtaactgacactgaggctcgaaagcgtggggagcaaacaggattagat accctggtagtccacgccgtaaacgatgagtgctagatgtagggagctataagttctctgtatcgcagctaacgcaat aagcactccgcctggggagtacgaccgcaaggttgaaactcaaaggaattgacgggggcccgcacaagcggtg gagcatgtggtttaattcgaagcaacgcgaagaaccttaccaggtcttgacatactcgtgctattcctagagatagga agttccttcgggacacgggatacaggtggtgcatggttgtcgtcagctcgtgtcgtgagatgttgggttaagtcccgc aacgagcgcaacccctattgttagttgccatcattaagttgggcactctaacgagactgccggtgataaaccggagg aaggtggggatgacgtcaaatcatcatgccccttatgacctgggctacacacgtgctacaatggatggtacaacgag tcgcgagacagtgatgtttagctaatctcttaaaaccattctcagttcggattgtaggctgcaactcgcctacatgaagt cggaatcgctagtaatcgcggatcagcacgccgcggtgaatacgttcccgggccttgtacacaccgcccgtcacac cacgggagttgggagtacccgaagtaggttgcctaaccgcaaggagggcgctcctaagtagaccgattg(SEQ IN NO.1)。
the cb18m1 strain was named Lactococcus lactis (Lactococcus lactis) MD-622 in combination with colony morphology and 16S sequence.
Lactococcus lactis (Lactococcus lactis) MD-622 was collected by the China general microbiological culture Collection center (CGMCC) at 11/15/2021, and culture conditions and survival conditions of the culture were as follows: all are cultured in lactic acid bacteria culture Medium (MRS) with pH of 6.2-6.6, and kept standing overnight in a constant temperature incubator at 37 ℃. Ultra-low temperature freezing for long-term storage is recommended.
Example 3 virulence experiments and safety testing
The cb18m1 strain is inspected, and a toxicological test and a safety test are carried out, and the results show that: the culture of the cb18m1 strain does not endanger human health or animal and plant pathogens or pollute the environment.
Example 4
Culturing bone cells (C3H10T1/2) by culturing C3H1OT1/2 cell line at 37 deg.C and 5% CO2The culture was performed in a DMEM high-sugar medium containing 10% fetal bovine serum, 100U/mL penicillin and 100. mu.g/mL streptomycin.
Continuously activating to-be-detected inactivated lactococcus lactis strain with MRS liquid culture medium for 3 generations, washing bacteria with sterile PBS buffer solution, and adjusting density to 3 × 108And (mL). Inoculating 2% volume of MRS liquid culture medium, shaking, sealing, and fermenting in 37 deg.C gas bath constant temperature oscillator; after 1 week, the fermentation broth was centrifuged at 4000 r/min for 30min, and the supernatant was filtered off with a 0.2 μm microfiltration membrane filter.
Experimental groups: the osteoblasts C3H10T1/2 were stimulated with supernatant from Lactococcus lactis (Lactococcus lactis) MD-622 to be inactivated.
The blank group was stimulated with the same volume of 2.0% formaldehyde as the experimental group.
The MTT method is used for detecting the growth condition of the cells, and the method comprises the following steps: the C3H1OT1/2 cells in logarithmic growth phase are randomly divided into a test group and a control group which are 5 multiplied by 105The cells were seeded in 96-well plates at a density of one mL/mL, 100. mu.L of RPMI-4640 cell culture (containing 10% fetal bovine serum) was added to each well, and the mixture was incubated at 37 ℃ with 5% CO2Culturing for 24h under the condition, and removing supernatant.
The experimental group was added with 200. mu.L of fermentation broth, the volume ratio of fermentation broth to cell culture fluid was 1: 4.
And adding 200 mu L of PBS buffer solution (the volume ratio of the PBS buffer solution to the cell culture solution is the same as that of the cell culture solution), continuously culturing for 72h, adding 10 mu L of tetrazolium blue MTT solution into each well, washing and removing supernatant after 4h, adding 150 mu L of dimethyl sulfoxide into each group of at least 6 parallel wells, and measuring the Optical Density (OD) value of each group at the wavelength of 570nm by using enzyme labeling.
The conversion, results are statistically shown in the following table:
statistical table of growth rate of osteocyte C3H10T1/2
Numbering | Name (R) | Bone cell C3H10T1/2 growth Rate (%) |
CK | Cells | 100.00% |
Blank space | Ctrl | 111.43% |
cb18m1 | Lactobacillus lactis | 81.72% |
As can be seen from the above table, the cb18m1 Lactobacillus lactis has an inhibitory effect on the growth of osteocytes C3H10T 1/2.
Example 5
Culturing mouse embryonic stem cells CE 3: embryonic stem cells were cultured in a culture medium of 90% DMEM (high glucose), 10% Fetal Bovine Serum (FBS), 1% penicillin, 1% streptomycin.
Continuously activating to-be-detected inactivated lactococcus lactis strain with MRS liquid culture medium for 3 generations, washing bacteria with sterile PBS buffer solution, and adjusting density to 3 × 108And (mL). Inoculating MRS liquid culture medium with 2% volume, and shakingHomogenizing, sealing, and fermenting in 37 deg.C gas bath constant temperature oscillator; after 1 week, the fermentation broth was centrifuged at 4000 r/min for 30min, and the supernatant was filtered off with a 0.2 μm microfiltration membrane filter.
The method for detecting the growth of the embryonic cells by using the MTT method through stimulating the supernatant of the inactivated strain Lactococcus lactis (Lactococcus lactis) MD-622 to be detected comprises the following steps:
the CE3 cells in logarithmic growth phase are randomly divided into a test group and a control group according to the ratio of 5 multiplied by 105The cells were seeded in 96-well plates at a density of one mL/mL, 100. mu.L of RPMI-4640 cell culture (containing 10% fetal bovine serum) was added to each well, and the mixture was incubated at 37 ℃ with 5% CO2Culturing under the condition for 24h, and removing supernatant.
The experimental group was added with 200. mu.L of fermentation broth, the volume ratio of fermentation broth to cell culture fluid was 1: 4.
And adding 200 mu L of PBS buffer solution (the volume ratio of the PBS buffer solution to the cell culture solution is the same as that of the cell culture solution), continuously culturing for 72h, adding 10 mu L of tetrazolium blue MTT solution into each well, washing and removing supernatant after 4h, adding 150 mu L of dimethyl sulfoxide into each group of at least 6 parallel wells, and measuring the Optical Density (OD) value of each group at the wavelength of 570nm by using enzyme labeling.
The conversion, results are statistically shown in the following table:
statistical table of growth rate of CE3 embryonic stem cells
Numbering | Name (R) | Growth rate (%) of embryonic Stem cell CE3 |
CK | Cells | 100.00% |
Blank space | Ctrl | 95.73% |
cb18m1 | Lactobacillus lactis | 126.54% |
As can be seen from the above table, the cb18m1 Lactobacillus lactis has a promoting effect on the growth and development of the embryonic stem cell CE 3.
Example 6
The embodiment provides a probiotic preparation containing Lactococcus lactis (Lactococcus lactis) MD-622, which comprises Lactococcus lactis MD-622 and preparation auxiliary materials.
In conclusion, the lactococcus lactis MD-622 is obtained by screening a large number of research tests, and the lactococcus lactis MD-622 can promote in vivo production of protease, amylase and cellulase, improve intestinal health and promote growth and development of embryonic stem cells to a certain extent.
It should be noted that the above examples are only for further illustration and description of the technical solution of the present invention, and are not intended to further limit the technical solution of the present invention, and the method of the present invention is only a preferred embodiment, and is not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Sequence listing
<110> Meiyi Adoration biomedical (Wuhan) Co., Ltd
<120> Lactobacillus lactis MD-622 and application thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1445
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
ggggcgtgtg ctatgatgca gttgagcgct gaaggttggt acttgtaccg actggatgag 60
cagcgaacgg gtgagtaacg cgtggggaat ctgcctttga gcgggggaca acatttggaa 120
acgaatgcta ataccgcata aaaactttaa acacaagttt taagtttgaa agatgcaatt 180
gcatcactca aagatgatcc cgcgttgtat tagctagttg gtgaggtaaa ggctcaccaa 240
ggcgatgata catagccgac ctgagagggt gatcggccac attgggactg agacacggcc 300
caaactccta cgggaggcag cagtagggaa tcttcggcaa tggacgaaag tctgaccgag 360
caacgccgcg tgagtgaaga aggttttcgg atcgtaaaac tctgttggta gagaagaacg 420
ttggtgagag tggaaagctc atcaagtgac ggtaactacc cagaaaggga cggctaacta 480
cgtgccagca gccgcggtaa tacgtaggtc ccgagcgttg tccggattta ttgggcgtaa 540
agcgagcgca ggtggtttat taagtctggt gtaaaaggca gtggctcaac cattgtatgc 600
attggaaact ggtagacttg agtgcaggag aggagagtgg aattccatgt gtagcggtga 660
aatgcgtaga tatatggagg aacaccggtg gcgaaagcgg ctctctggcc tgtaactgac 720
actgaggctc gaaagcgtgg ggagcaaaca ggattagata ccctggtagt ccacgccgta 780
aacgatgagt gctagatgta gggagctata agttctctgt atcgcagcta acgcaataag 840
cactccgcct ggggagtacg accgcaaggt tgaaactcaa aggaattgac gggggcccgc 900
acaagcggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac caggtcttga 960
catactcgtg ctattcctag agataggaag ttccttcggg acacgggata caggtggtgc 1020
atggttgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcaacg agcgcaaccc 1080
ctattgttag ttgccatcat taagttgggc actctaacga gactgccggt gataaaccgg 1140
aggaaggtgg ggatgacgtc aaatcatcat gccccttatg acctgggcta cacacgtgct 1200
acaatggatg gtacaacgag tcgcgagaca gtgatgttta gctaatctct taaaaccatt 1260
ctcagttcgg attgtaggct gcaactcgcc tacatgaagt cggaatcgct agtaatcgcg 1320
gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac acaccgcccg tcacaccacg 1380
ggagttggga gtacccgaag taggttgcct aaccgcaagg agggcgctcc taagtagacc 1440
gattg 1445
Claims (9)
1. Lactococcus lactis MD-622 has been deposited in China general microbiological culture Collection center (CGMCC) at 11 months and 15 days 2021 with the deposition number of CGMCC No. 23902.
2. Lactococcus lactis MD-622 according to claim 1, wherein the lactococcus lactis has the 16S rRNA sequence shown in SEQ ID No. 1.
3. Lactococcus lactis MD-622 according to claim 1, wherein said lactococcus lactis is cultured under conditions selected from the group consisting of: MRS culture medium, pH6.2-6.6.
4. Lactococcus lactis MD-622 according to claim 1, wherein said lactococcus lactis is capable of producing a protease, an amylase, a cellulase.
5. A composition comprising lactococcus lactis MD-622 as set forth in any one of claims 1 to 4.
6. Use of lactococcus lactis MD-622 and its secretory products or metabolites according to any one of claims 1 to 4 in the preparation of probiotic products.
7. The use according to claim 6, wherein the probiotic product is a drug, functional food or health product for improving intestinal diseases, or a drug, functional food or health product for promoting the growth and development of embryonic stem cells.
8. A probiotic, characterized by comprising lactococcus lactis MD-622 according to any one of claims 1 to 4, the composition according to claim 5.
9. The probiotic according to claim 8, characterized in that it further comprises an adjuvant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111586675.5A CN114480167B (en) | 2021-12-23 | 2021-12-23 | Lactococcus lactis MD-622 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111586675.5A CN114480167B (en) | 2021-12-23 | 2021-12-23 | Lactococcus lactis MD-622 and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114480167A true CN114480167A (en) | 2022-05-13 |
CN114480167B CN114480167B (en) | 2024-01-12 |
Family
ID=81493566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111586675.5A Active CN114480167B (en) | 2021-12-23 | 2021-12-23 | Lactococcus lactis MD-622 and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114480167B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115181695A (en) * | 2022-06-27 | 2022-10-14 | 广东粤港澳大湾区国家纳米科技创新研究院 | Lactobacillus plantarum5b4m2 and application thereof |
CN117660246A (en) * | 2023-12-06 | 2024-03-08 | 河北一然生物科技股份有限公司 | Lactococcus lactis subspecies S28 for high-yield metabolic enzyme and application thereof |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010051250A (en) * | 2008-08-28 | 2010-03-11 | Ezaki Glico Co Ltd | Cacao fermented product and method for producing the same |
CN102834520A (en) * | 2009-10-30 | 2012-12-19 | 生物基因创新有限责任公司 | Use of methylsulfonylmethane (MSM) to modulate microbial activity |
RU2013125554A (en) * | 2013-06-03 | 2014-12-10 | Федеральное государственное бюджетное учреждение науки Институт проблем экологии и эволюции им. А.Н. Северцова Академии Наук | METHOD FOR PRODUCING FODDER PROBIOTIC DRUG FOR AGRICULTURAL ANIMALS |
CN106987613A (en) * | 2017-04-13 | 2017-07-28 | 安徽瑞福祥食品有限公司 | A kind of industrialized process for preparing of wheat gluten peptone and application thereof |
CN107699527A (en) * | 2017-11-21 | 2018-02-16 | 广东海洋大学 | A kind of probiotics micro-ecological formulation and its preparation method and application |
CN109022330A (en) * | 2018-09-12 | 2018-12-18 | 内蒙古农业大学 | One plant has high proteolytic ability and produces Lactococcus lactis BL19 and its application of junket fragrance |
WO2019043189A1 (en) * | 2017-09-01 | 2019-03-07 | Novozymes A/S | Animal feed additives comprising polypeptide having protease activity and uses thereof |
WO2019174001A1 (en) * | 2018-03-15 | 2019-09-19 | 江南大学 | Lactococcus lactis subsp. lactis ccfm1018, fermented food thereof and application thereof in preparing drug |
WO2020012467A2 (en) * | 2018-07-08 | 2020-01-16 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
CA3088187A1 (en) * | 2019-11-18 | 2020-11-09 | Ziolase, Llc | Compositions and methods to prevent and treat biofilms |
KR102310337B1 (en) * | 2020-12-04 | 2021-10-07 | 주식회사 큐옴바이오 | Lactococcus lactis q1 strain having complex digestive productivity and antibacterial activity and uses thereof |
CN114437969A (en) * | 2022-01-24 | 2022-05-06 | 美益添生物医药(武汉)有限公司 | Lactobacillus acidophilus MD-286 and application thereof |
CN116211764A (en) * | 2022-12-30 | 2023-06-06 | 广东粤港澳大湾区国家纳米科技创新研究院 | Composition, fermentation product thereof and application of fermentation product in preparation of cosmetics |
-
2021
- 2021-12-23 CN CN202111586675.5A patent/CN114480167B/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010051250A (en) * | 2008-08-28 | 2010-03-11 | Ezaki Glico Co Ltd | Cacao fermented product and method for producing the same |
CN102834520A (en) * | 2009-10-30 | 2012-12-19 | 生物基因创新有限责任公司 | Use of methylsulfonylmethane (MSM) to modulate microbial activity |
RU2013125554A (en) * | 2013-06-03 | 2014-12-10 | Федеральное государственное бюджетное учреждение науки Институт проблем экологии и эволюции им. А.Н. Северцова Академии Наук | METHOD FOR PRODUCING FODDER PROBIOTIC DRUG FOR AGRICULTURAL ANIMALS |
CN106987613A (en) * | 2017-04-13 | 2017-07-28 | 安徽瑞福祥食品有限公司 | A kind of industrialized process for preparing of wheat gluten peptone and application thereof |
WO2019043189A1 (en) * | 2017-09-01 | 2019-03-07 | Novozymes A/S | Animal feed additives comprising polypeptide having protease activity and uses thereof |
CN107699527A (en) * | 2017-11-21 | 2018-02-16 | 广东海洋大学 | A kind of probiotics micro-ecological formulation and its preparation method and application |
WO2019174001A1 (en) * | 2018-03-15 | 2019-09-19 | 江南大学 | Lactococcus lactis subsp. lactis ccfm1018, fermented food thereof and application thereof in preparing drug |
WO2020012467A2 (en) * | 2018-07-08 | 2020-01-16 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
CN109022330A (en) * | 2018-09-12 | 2018-12-18 | 内蒙古农业大学 | One plant has high proteolytic ability and produces Lactococcus lactis BL19 and its application of junket fragrance |
CA3088187A1 (en) * | 2019-11-18 | 2020-11-09 | Ziolase, Llc | Compositions and methods to prevent and treat biofilms |
KR102310337B1 (en) * | 2020-12-04 | 2021-10-07 | 주식회사 큐옴바이오 | Lactococcus lactis q1 strain having complex digestive productivity and antibacterial activity and uses thereof |
CN114437969A (en) * | 2022-01-24 | 2022-05-06 | 美益添生物医药(武汉)有限公司 | Lactobacillus acidophilus MD-286 and application thereof |
CN116211764A (en) * | 2022-12-30 | 2023-06-06 | 广东粤港澳大湾区国家纳米科技创新研究院 | Composition, fermentation product thereof and application of fermentation product in preparation of cosmetics |
Non-Patent Citations (3)
Title |
---|
JAKE J HAY等: "Living biointerfaces based on non-pathogenic bacteria support stem cell differentiation", SCI REP, vol. 6, pages 1 - 10 * |
孙宁;雷敬玲;吴晓青;黄丽;李玲;黄子珍;: "自然发酵酸笋中乳酸菌的筛选鉴定及益生特性研究", 中国酿造, no. 06, pages 67 - 72 * |
胡学智;王俊;: "益生菌饲料的现状、生产和应用效果(一)", 中国微生态学杂志, no. 09, pages 861 - 864 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115181695A (en) * | 2022-06-27 | 2022-10-14 | 广东粤港澳大湾区国家纳米科技创新研究院 | Lactobacillus plantarum5b4m2 and application thereof |
CN115181695B (en) * | 2022-06-27 | 2023-08-29 | 广东粤港澳大湾区国家纳米科技创新研究院 | Lactobacillus plantarum5b4m2 and application thereof |
CN117660246A (en) * | 2023-12-06 | 2024-03-08 | 河北一然生物科技股份有限公司 | Lactococcus lactis subspecies S28 for high-yield metabolic enzyme and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114480167B (en) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105219683B (en) | One plant of L. reuteri strain with prebiotic characteristics and its application | |
CN101864375B (en) | Lactobacillu plantarurn with function of reducing cholesterol and application thereof | |
CN108251335B (en) | Enterococcus faecalis HKF7 with lactic acid activity and screening culture method and application thereof | |
CN113980878A (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof | |
CN108728382A (en) | One plant of tool norcholesterol and lactobacillus plantarum and its application for promoting enteron aisle short chain fatty acids generation ability | |
CN105132318A (en) | Lactobacillus plantarum grx16 and application thereof | |
CN109749957B (en) | Preparation and application of lactobacillus gasseri preparation with aquatic pathogenic bacteria antagonistic property | |
CN109161498B (en) | Bacillus subtilis M406 and application thereof in preparation of bacteriocin and cellulase | |
CN114480167A (en) | Lactococcus lactis MD-622 and application thereof | |
CN101691550A (en) | Microbial inoculum for improving water body and structure of biological intestinal colony, and preparation method and application thereof | |
KR101729478B1 (en) | Immune regulating tyndalized lactic acid bacteria and a method for manufacturing the same | |
CN110791460B (en) | Strain for inhibiting growth of aspergillus flavus and generation of toxin | |
CN113652373A (en) | Bacillus and application thereof | |
CN116970512A (en) | Lactobacillus plantarum, and culture method and application thereof | |
CN107937316B (en) | Space lactobacillus reuteri Fullarton-9-71 and application | |
CN107974424B (en) | Space lactobacillus reuteri Fullarton-9-25 and application | |
CN107828703A (en) | Space lactobacillus reuteri Fullarton 9 35 and application | |
CN107974425B (en) | Space lactobacillus reuteri Fullarton-9-79 and application | |
JP2019517810A (en) | Bacillus licheniformis NY1505 strain producing a large amount of α-glucosidase inhibitor | |
CN115838652B (en) | Lactobacillus reuteri LR21 and application thereof | |
CN111647523B (en) | Probiotic composition for stichopus japonicus culture and application thereof | |
CN113881592B (en) | Lactobacillus reuteri and application thereof | |
CN113215067B (en) | VBNC (viable but non-viable) state lactobacillus brevis CSHRR5-3 strain and application thereof | |
CN113956993B (en) | Lactobacillus paracasei with effect of relieving oxidative damage of human keratinocytes | |
CN114806953A (en) | Lactobacillus gasseri with characteristic of improving type 1 diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |